MX2022012739A - Derivados de piridopirimidinona y su uso como moduladores del receptor de hidrocarburos de arilo. - Google Patents
Derivados de piridopirimidinona y su uso como moduladores del receptor de hidrocarburos de arilo.Info
- Publication number
- MX2022012739A MX2022012739A MX2022012739A MX2022012739A MX2022012739A MX 2022012739 A MX2022012739 A MX 2022012739A MX 2022012739 A MX2022012739 A MX 2022012739A MX 2022012739 A MX2022012739 A MX 2022012739A MX 2022012739 A MX2022012739 A MX 2022012739A
- Authority
- MX
- Mexico
- Prior art keywords
- ahr
- aryl hydrocarbon
- hydrocarbon receptor
- receptor modulators
- disease
- Prior art date
Links
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 title abstract 6
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 title abstract 6
- IAAQUOVTPAMQCR-UHFFFAOYSA-N 1h-pyrido[3,2-d]pyrimidin-2-one Chemical class C1=CC=C2NC(=O)N=CC2=N1 IAAQUOVTPAMQCR-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se relaciona con compuestos novedosos efectivos como moduladores del receptor de hidrocarburos de arilo (AhR), composición farmacéutica que comprende los compuestos para la modulación de AhR, o la prevención o tratamiento de una enfermedad, trastorno o condición asociada con la actividad de AhR, como ingrediente activo, y por lo tanto, puede ser útil como medicamento para la prevención o el tratamiento de una enfermedad, trastorno o afección asociada con la actividad de AhR, en particular, cáncer, afección cancerosa, tumor, enfermedad fibrótica, afección con respuestas inmunitarias desreguladas, etc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063011351P | 2020-04-17 | 2020-04-17 | |
| PCT/KR2021/004904 WO2021210970A1 (en) | 2020-04-17 | 2021-04-19 | Pyridopyrimidinone derivatives and their use as aryl hydrocarbon receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012739A true MX2022012739A (es) | 2022-11-07 |
Family
ID=78084339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012739A MX2022012739A (es) | 2020-04-17 | 2021-04-19 | Derivados de piridopirimidinona y su uso como moduladores del receptor de hidrocarburos de arilo. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230147257A1 (es) |
| EP (1) | EP4136088A4 (es) |
| JP (1) | JP2023522045A (es) |
| KR (1) | KR20230005188A (es) |
| CN (1) | CN115443276A (es) |
| AU (1) | AU2021257373B2 (es) |
| BR (1) | BR112022020965A2 (es) |
| CA (1) | CA3178129A1 (es) |
| MX (1) | MX2022012739A (es) |
| WO (1) | WO2021210970A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL293103A (en) * | 2019-11-22 | 2022-07-01 | Senda Biosciences Inc | History of pyridopyrimidinones as ahr antagonists |
| CN114644627A (zh) * | 2020-12-18 | 2022-06-21 | 山东轩竹医药科技有限公司 | AhR抑制剂及其用途 |
| WO2022217042A1 (en) * | 2021-04-09 | 2022-10-13 | Ikena Oncology, Inc. | Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions |
| WO2024008722A2 (en) * | 2022-07-04 | 2024-01-11 | Muna Therapeutics Aps | Trem2 modulators |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2519673C2 (ru) * | 2008-11-28 | 2014-06-20 | Новартис Аг | Комбинации ингибитора hsp90 |
| AU2015279047B2 (en) * | 2014-06-27 | 2020-01-02 | Nogra Pharma Limited | Aryl receptor modulators and methods of making and using the same |
| TW201942115A (zh) * | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
| CN111683950B (zh) * | 2018-02-06 | 2024-04-16 | 伊迪亚生物科学有限公司 | AhR调节剂 |
| JP2021535213A (ja) * | 2018-08-24 | 2021-12-16 | ジャガー セラピューティクス ピーティーイーリミテッド | ＡｈＲモジュレーターとしてのテトラヒドロピリドピリミジン誘導体 |
| JP2021536458A (ja) * | 2018-09-04 | 2021-12-27 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | アリール炭化水素レセプター・アンタゴニスト及び使用方法 |
| CN111961034A (zh) * | 2019-05-20 | 2020-11-20 | 浙江同源康医药股份有限公司 | 用作ret激酶抑制剂的化合物及其应用 |
| IL293103A (en) * | 2019-11-22 | 2022-07-01 | Senda Biosciences Inc | History of pyridopyrimidinones as ahr antagonists |
| CN116745622A (zh) * | 2020-10-13 | 2023-09-12 | 先达生物科技公司 | 与免疫检查点抑制剂疗法相关的生物标志物及其使用方法 |
| CN114644627A (zh) * | 2020-12-18 | 2022-06-21 | 山东轩竹医药科技有限公司 | AhR抑制剂及其用途 |
-
2021
- 2021-04-19 MX MX2022012739A patent/MX2022012739A/es unknown
- 2021-04-19 US US17/906,745 patent/US20230147257A1/en active Pending
- 2021-04-19 AU AU2021257373A patent/AU2021257373B2/en active Active
- 2021-04-19 JP JP2022562929A patent/JP2023522045A/ja active Pending
- 2021-04-19 CN CN202180028538.1A patent/CN115443276A/zh active Pending
- 2021-04-19 WO PCT/KR2021/004904 patent/WO2021210970A1/en unknown
- 2021-04-19 KR KR1020227037505A patent/KR20230005188A/ko active Search and Examination
- 2021-04-19 CA CA3178129A patent/CA3178129A1/en active Pending
- 2021-04-19 BR BR112022020965A patent/BR112022020965A2/pt unknown
- 2021-04-19 EP EP21789177.9A patent/EP4136088A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230005188A (ko) | 2023-01-09 |
| EP4136088A1 (en) | 2023-02-22 |
| BR112022020965A2 (pt) | 2022-12-06 |
| AU2021257373B2 (en) | 2024-03-21 |
| CN115443276A (zh) | 2022-12-06 |
| JP2023522045A (ja) | 2023-05-26 |
| WO2021210970A1 (en) | 2021-10-21 |
| US20230147257A1 (en) | 2023-05-11 |
| EP4136088A4 (en) | 2024-05-08 |
| CA3178129A1 (en) | 2021-10-21 |
| AU2021257373A1 (en) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012739A (es) | Derivados de piridopirimidinona y su uso como moduladores del receptor de hidrocarburos de arilo. | |
| Good et al. | Intralesional agents in the management of cutaneous malignancy: a review | |
| EP4324460A3 (en) | Sodium bicarbonate for use in the treatment of gout and related disorders | |
| MX2022012780A (es) | Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados. | |
| WO2019099977A3 (en) | Indole compounds as aryl hydrocarbon receptor (ahr) modulators | |
| MX2023008895A (es) | Conjugado de sustancia bioactiva, metodo de preparacion y uso del mismo. | |
| MX2018001659A (es) | Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer. | |
| WO2016018920A8 (en) | Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
| MX2023009521A (es) | Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d. | |
| MX2023000056A (es) | Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f). | |
| Greb et al. | High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum. | |
| EA202190059A1 (ru) | Конъюгаты связующее-активное средство, направленные против cxcr5, имеющие ферментативно расщепляемые линкеры и улучшенный профиль активности | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| MX2022014924A (es) | Moduladores de il-17a. | |
| MX2022014925A (es) | Moduladores de il-17a. | |
| JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| PH12021551446A1 (en) | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 | |
| BR112013024909A2 (pt) | composto, composição farmacêutica, método para o tratamento, prevenção ou melhoria de um ou mais sintomas de desordem, doença, ou condição mediada por pi3k, e método para modular a atividade enzimática de pi3k | |
| MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2022015739A (es) | Inhibidores alostericos de egfr y metodos de uso de estos. |